27508301|t|Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy
27508301|a|Cardiovascular disease (CVD) is a leading health threat for HIV+ patients on antiretroviral therapy (ART); cardiometabolic comorbidities are key predictors of risk. Data are limited on incidence of metabolic comorbidities in HIV+ individuals initiating ART in low and middle income countries (LMICs), particularly for Hispanics. We examined incidence of diabetes and obesity in a prospective cohort of those initiating ART in the Dominican Republic. Participants ≥18 years, initiating ART <90 days prior to study enrollment, were examined for incidence of impaired fasting glucose (IFG), diabetes mellitus (DM), overweight, and obesity. Fasting plasma glucose (FPG) 100-125mg/dl defined IFG; FPG ≥126 mg/dl, diagnosis per medical record, or use of hypoglycemic medication defined DM. Overweight and obesity were BMI 25-30 and ≥30kg/m2, respectively. Dyslipidemia was total cholesterol ≥240mg/dl or use of lipid-lowering medication. Framingham risk equation was used to determine ten-year CVD risk at the end of observation. Of 153 initiating ART, 8 (6%) had DM and 23 (16%) had IFG at baseline, 6 developed DM (28/1000 person - years follow up [PYFU]) and 46 developed IFG (329/1000 PYFU). At baseline, 24 (18%) were obese and 36 (27%) were overweight, 15 became obese (69/1000 PYFU) and 22 became overweight (163/1000 PYFU). Median observation periods for the diabetes and obesity analyses were 23.5 months and 24.3 months, respectively. Increased CVD risk (≥10% 10-year Framingham risk score) was present for 13% of the cohort; 79% of the cohort had ≥1 cardiometabolic comorbidity, 48% had ≥2, and 13% had all three. In this Hispanic cohort in an LMIC, incidences of IFG / DM and overweight / obesity were similar to or higher than that found in high income countries, and cardiometabolic disorders affected three-quarters of those initiating ART. Care models incorporating cardiovascular risk reduction into HIV treatment programs are needed to prevent CVD - associated mortality in this vulnerable population.
27508301	13	30	Diabetes Mellitus	T038	UMLS:C0011849
27508301	35	42	Obesity	T038	UMLS:C0028754
27508301	79	83	HIV+	T033	UMLS:C0019699
27508301	84	93	Hispanics	T098	UMLS:C0086409
27508301	105	127	Antiretroviral Therapy	T058	UMLS:C1963724
27508301	128	150	Cardiovascular disease	T038	UMLS:C0007222
27508301	152	155	CVD	T038	UMLS:C0007222
27508301	188	192	HIV+	T033	UMLS:C0019699
27508301	205	227	antiretroviral therapy	T058	UMLS:C1963724
27508301	229	232	ART	T058	UMLS:C1963724
27508301	235	250	cardiometabolic	T038	UMLS:C0025517
27508301	273	291	predictors of risk	T033	UMLS:C0035648
27508301	353	357	HIV+	T033	UMLS:C0019699
27508301	358	369	individuals	T098	UMLS:C0237401
27508301	381	384	ART	T058	UMLS:C1963724
27508301	410	419	countries	T082	UMLS:C0454664
27508301	421	426	LMICs	T082	UMLS:C0454664
27508301	446	455	Hispanics	T098	UMLS:C0086409
27508301	460	468	examined	T033	UMLS:C0332128
27508301	482	490	diabetes	T038	UMLS:C0011847
27508301	495	502	obesity	T038	UMLS:C0028754
27508301	508	526	prospective cohort	T098	UMLS:C0599755
27508301	547	550	ART	T058	UMLS:C1963724
27508301	558	576	Dominican Republic	T082	UMLS:C0013014
27508301	578	590	Participants	T098	UMLS:C0679646
27508301	613	616	ART	T058	UMLS:C1963724
27508301	635	640	study	T062	UMLS:C2603343
27508301	641	651	enrollment	T058	UMLS:C1516879
27508301	658	666	examined	T033	UMLS:C0332128
27508301	684	708	impaired fasting glucose	T033	UMLS:C1272092
27508301	710	713	IFG	T033	UMLS:C1272092
27508301	716	733	diabetes mellitus	T038	UMLS:C0011849
27508301	735	737	DM	T038	UMLS:C0011849
27508301	740	763	overweight, and obesity	T038	UMLS:C1561826
27508301	765	787	Fasting plasma glucose	T058	UMLS:C0583513
27508301	789	792	FPG	T058	UMLS:C0583513
27508301	815	818	IFG	T033	UMLS:C1272092
27508301	820	823	FPG	T058	UMLS:C0583513
27508301	836	845	diagnosis	T062	UMLS:C1704656
27508301	850	864	medical record	T170	UMLS:C0025102
27508301	876	899	hypoglycemic medication	T103	UMLS:C0020616
27508301	908	910	DM	T038	UMLS:C0011849
27508301	912	934	Overweight and obesity	T038	UMLS:C1561826
27508301	940	943	BMI	T201	UMLS:C1305855
27508301	978	990	Dyslipidemia	T038	UMLS:C0242339
27508301	995	1012	total cholesterol	T103	UMLS:C0543421
27508301	1033	1058	lipid-lowering medication	T103	UMLS:C0003367
27508301	1089	1093	used	T033	UMLS:C1273517
27508301	1116	1119	CVD	T038	UMLS:C0007222
27508301	1120	1124	risk	T058	UMLS:C0086930
27508301	1132	1150	end of observation	T062	UMLS:C0302523
27508301	1170	1173	ART	T058	UMLS:C1963724
27508301	1186	1188	DM	T038	UMLS:C0011849
27508301	1206	1209	IFG	T033	UMLS:C1272092
27508301	1235	1237	DM	T038	UMLS:C0011849
27508301	1247	1253	person	T098	UMLS:C0027361
27508301	1262	1271	follow up	T058	UMLS:C1522577
27508301	1273	1277	PYFU	T058	UMLS:C1522577
27508301	1297	1300	IFG	T033	UMLS:C1272092
27508301	1311	1315	PYFU	T058	UMLS:C1522577
27508301	1345	1350	obese	T038	UMLS:C0028754
27508301	1369	1379	overweight	T033	UMLS:C0497406
27508301	1391	1396	obese	T038	UMLS:C0028754
27508301	1406	1410	PYFU	T058	UMLS:C1522577
27508301	1426	1436	overweight	T033	UMLS:C0497406
27508301	1447	1451	PYFU	T058	UMLS:C1522577
27508301	1454	1460	Median	T082	UMLS:C2939193
27508301	1461	1472	observation	T058	UMLS:C0700325
27508301	1489	1497	diabetes	T038	UMLS:C0011847
27508301	1502	1509	obesity	T038	UMLS:C0028754
27508301	1510	1518	analyses	T062	UMLS:C0936012
27508301	1577	1580	CVD	T038	UMLS:C0007222
27508301	1581	1585	risk	T058	UMLS:C0086930
27508301	1592	1621	10-year Framingham risk score	T033	UMLS:C4086295
27508301	1627	1634	present	T033	UMLS:C0150312
27508301	1650	1656	cohort	T098	UMLS:C0599755
27508301	1669	1675	cohort	T098	UMLS:C0599755
27508301	1755	1763	Hispanic	T098	UMLS:C0086409
27508301	1764	1770	cohort	T098	UMLS:C0599755
27508301	1777	1781	LMIC	T082	UMLS:C0454664
27508301	1797	1800	IFG	T033	UMLS:C1272092
27508301	1803	1805	DM	T038	UMLS:C0011849
27508301	1810	1820	overweight	T033	UMLS:C0497406
27508301	1823	1830	obesity	T038	UMLS:C0028754
27508301	1867	1872	found	T033	UMLS:C0150312
27508301	1876	1887	high income	T033	UMLS:C0948433
27508301	1888	1897	countries	T082	UMLS:C0454664
27508301	1903	1928	cardiometabolic disorders	T038	UMLS:C0025517
27508301	1973	1976	ART	T058	UMLS:C1963724
27508301	2024	2033	reduction	T058	UMLS:C0441610
27508301	2039	2042	HIV	T038	UMLS:C0019693
27508301	2084	2087	CVD	T038	UMLS:C0007222
27508301	2119	2140	vulnerable population	T098	UMLS:C0949366